文献速递生殖医学

医学指征生育力保存中胚胎冻存时PGT-A的预后作用

Prognostic role of preimplantation genetic testing for aneuploidy in medically indicated fertility preservation.
PubMed 文献 · Fertil Steril · 2020-01-20

回顾性队列研究分析2014年1月至2018年4月因医学指征行胚胎冻存(EB)的58个周期,其中34个周期使用PGT-A。PGT-A使用随时间增加,未限制卵母细胞冻存等其他生育力保存方法;部分PGT-A结果不佳者选择再次EB周期。咨询时需权衡PGT-A的预后益处与费用及「终末」生育诊断风险。

要点

  • 医学指征EB周期中PGT-A使用率随时间上升,且未限制卵母细胞冻存等其他保存方法。
  • PGT-A组平均检测6.7±5个囊胚,冻存3.5±3个(48.2%)整倍体胚胎;非PGT-A组平均冻存7.2±7个未检测胚胎。
  • 部分PGT-A结果不佳者据此选择再次EB周期,咨询需权衡预后益处与费用及「终末」生育诊断风险。

核心结论

  • 医学指征EB周期中PGT-A使用随时间增加,未限制卵母细胞冻存等其他生育力保存方法。
  • 部分病例中PGT-A结果不佳促使患者选择再次EB周期。
  • 咨询时需权衡PGT-A的预后益处与费用及潜在「终末」生育诊断风险。

研究设计与样本

  • 回顾性队列研究,纳入2014年1月至2018年4月因医学指征行生育力保存而接受体外受精(伴或不伴PGT-A)的所有患者,共比较58个医学EB周期,其中34个周期使用PGT-A。

主要发现

  • 乳腺癌EB患者中67%使用PGT-A,其他指征在PGT-A组(FP/PGT-A)与非PGT-A组(FP)间均匀分布。
  • 两组年龄、刺激天数及从初始生育力保存咨询到治疗开始的天数相似。
  • 两组冻存的卵母细胞数(FP组14.5[2-63] vs FP/PGT-A组17.5[1-64])、2PN受精卵数(7[1-38] vs 9[0-36])及囊胚数(5.5[0-22] vs 5[0-18])相似。
  • FP/PGT-A组中5例患者进行了第二个EB周期。
  • FP/PGT-A组平均6.7±5个囊胚接受PGT-A检测,冻存3.5±3个(48.2%)整倍体胚胎用于未来FET;FP组平均冻存7.2±7个未检测胚胎。

临床怎么用

  • 医学指征胚胎冻存时可考虑PGT-A,其使用未妨碍卵母细胞冻存等其他生育力保存方法。
  • 咨询时应告知PGT-A的预后益处、费用及可能得出「终末」生育诊断的风险,部分结果不佳者可选择再次EB周期。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the use of preimplantation genetic testing for aneuploidy (PGT-A) among patients pursuing embryo banking (EB) for medically indicated fertility preservation (FP). DESIGN: Retrospective cohort. SETTING: University-affiliated fertility center. PATIENTS: All patients who underwent in vitro fertilization with or without PGT-A for medically indicated FP between January 2014 and April 2018. INTERVENTIONS: None MAIN OUTCOME MEASURES: EB cycle characteristics, subsequent cycle pursuit/outcomes, and frozen embryo transfer (FET) outcomes. RESULTS: A total of 58 medical EB cycles were compared; 34 cycles used PGT-A. Of the EB patients with breast cancer, 67% used PGT-A; other indications were evenly divided between PGT-A (FP/PGT-A) and no PGT-A (FP). PGT-A use increased over the study period. Groups were similar in age, days of stimulation, and days from initial FP consultation to treatment initiation. Number of oocytes (14.5 [2-63] FP vs. 17.5 [1-64] FP/PGT-A), 2PN zygotes (7 [1-38] FP vs. 9 [0-36] FP/PGT-A), and blastocysts (5.5 [0-22] FP vs. 5 [0-18] FP/PGT-A) cryopreserved were similar between groups. Equal numbers cryopreserved both oocytes and embryos (5 vs. 3). Five FP/PGT-A patients underwent a second EB cycle. Among FP/PGT-A patients, an average of 6.7 ± 5 blastocysts underwent PGT-A, with 3.5 ± 3 (48.2%) euploid embryos cryopreserved for future FET compared to an average of 7.2 ± 7 untested embryos in the FP group. CONCLUSION: PGT-A in medical EB cycles increased over time and did not limit the use of other FP methods such as oocyte cryopreservation. In some cases, poor PGT-A results informed patients to pursue a second EB cycle. When counseling patients, the prognostic benefits of PGT-A must be weighed against the financial costs and potential for "terminal" fertility diagnosis.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Blakemore JK, Trawick EC, Grifo JA, et al. Prognostic role of preimplantation genetic testing for aneuploidy in medically indicated fertility preservation. Fertil Steril. 2020. PMID: 31973902. doi:10.1016/j.fertnstert.2019.09.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。